From Wikipedia, the free encyclopedia
Chemical compound
Mozavaptan
|
|
Routes of administration | Oral |
---|
ATC code | |
---|
|
Legal status |
- In general: ℞ (Prescription only)
|
---|
|
N-[4-(5-Dimethylamino-2,3,4,5-tetrahydro-1-benzazepine-1-carbonyl)phenyl]-2-methylbenzamide
|
CAS Number | |
---|
PubChem
CID | |
---|
IUPHAR/BPS | |
---|
ChemSpider | |
---|
UNII | |
---|
ChEMBL | |
---|
CompTox Dashboard (
EPA) | |
---|
|
Formula | C27H29N3O2 |
---|
Molar mass | 427.548 g·mol−1 |
---|
3D model (
JSmol) | |
---|
Cc1ccccc1C(=O)Nc2ccc(cc2)C(=O)N3c4ccccc4C(CCC3)N(C)C
|
InChI=1S/C27H29N3O2/c1-19-9-4-5-10-22(19)26(31)28-21-16-14-20(15-17-21)27(32)30-18-8-13-24(29(2)3)23-11-6-7-12-25(23)30/h4-7,9-12,14-17,24H,8,13,18H2,1-3H3,(H,28,31) YKey:WRNXUQJJCIZICJ-UHFFFAOYSA-N Y
|
NY
(what is this?)
(verify) |
Mozavaptan (
INN) is a
vasopressin receptor antagonist marketed by
Otsuka. In Japan, it was approved in October 2006 for
hyponatremia (low blood
sodium levels) caused by
syndrome of inappropriate antidiuretic hormone (SIADH) due to ADH producing tumors.
References
- Spreitzer H (November 20, 2006). "Neue Wirkstoffe - Conivaptan". Österreichische Apothekerzeitung (in German) (24/2006).
-
"Conivaptan hydrochloride". Molecule of the Month. Prous Science. November 2006. Archived from
the original on 2012-02-13.